Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 2: ST-Segment Elevation.

Slides:

Advertisements

Similar presentations

A Pharmaco-invasive Reperfusion Strategy with Immediate Percutaneous Coronary Intervention is Safe and Effective in ST-Elevation Myocardial Infarction.

Advertisements

Acute STEMI: current approach

Acute Coronary Syndromes SIGN 93. MINAP Mortality after Acute Coronary Syndromes Cumulative: 13.6% Blue 10.6% Green 11.6% Red.

Date of download: 5/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: The thrombolysis in myocardial infarction risk score.

Sex- and Gender-Related Risk Factor Burden in Patients With Premature Acute Coronary Syndrome Jin Choi, MSc, Stella Styliani Daskalopoulou, MD, MSc, PhD,

Date of download: 6/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2007 Focused Update of the ACC/AHA 2004 Guidelines.

From: Contemporary Mortality Risk Prediction for Percutaneous Coronary Intervention: Results From 588,398 Procedures in the National Cardiovascular Data.

MYOCARDIAL INFARCTION WITH LEFT BUNDLE BRANCH BLOCK: A DEADLY DISEASE WITH A LOW RATE OF REPERFUSION TREATMENT L. Lambert, L. Azzi, N. Racine, A. Tanguay,

Arch Intern Med. 2007;167(1): doi: /archinte Figure Legend:

Electrocardiographic Criteria for Detecting Acute Myocardial Infarction in Patients With Left Bundle Branch Block: A Meta-analysis Jeffrey A. Tabas,

Aligning Health Care Policy With Evidence-Based Medicine: The Case for Funding Direct Oral Anticoagulants in Atrial Fibrillation James A. Stone, MD,

Volume 81, Issue 10, Pages (October 2010)

Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy Jean-François Tanguay, MD, CSPQ, FRCPC, FACC,

ISCHEMIC AND BLEEDING EVENTS IN CANADIAN PATIENTS WITH MYOCARDIAL INFARCTION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION WHO REQUIRE ORAL ANTICOAGULATION:

Initial pharmacotherapy for ST-segment elevation myocardial infarction

Initial pharmacotherapy for ST-segment elevation myocardial infarction

A Novel Approach to Cardiovascular Health By Optimizing Risk Management (ANCHOR): Behavioural Modification in Primary Care Effectively Reduces Global.

A Novel Approach to Cardiovascular Health By Optimizing Risk Management (ANCHOR): Behavioural Modification in Primary Care Effectively Reduces Global.

Ischaemic Heart Disease Acute Coronary Syndrome

The Evolution of Myocardial Infarction: When the Truths We Hold To Be Self-Evident No Longer Have Evidence David D. Waters, MD, Sripal Bangalore, MD,

Canadian Cardiovascular Society/Canadian Cardiovascular Critical Care Society/Canadian Association of Interventional Cardiology Position Statement on.

The Demise of Morphine Oxygen Nitroglycerin Aspirin (MONA)

Laszlo Littmann, MD, PhD The American Journal of Medicine

2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Laurent Macle, MD, John Cairns, MD, Kori.

Contemporary Diagnosis and Management of Unstable Angina

R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R

Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control

2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy

Glenn N. Levine et al. JACC 2016;68:

Manuel Caceres, MD, Darryl S. Weiman, MD, JD

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Sudden Cardiac Death From the Perspective of Coronary Artery Disease

The following slides are based on a presentation at a Satellite Symposium in association with the Annual Cardiovascular Conference at Lake Louise, Alberta,

Eugene Braunwald, MD, Marc S. Sabatine, MD, MPH

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Canadian Cardiovascular Society Guidelines for the Diagnosis and Management of Stable Ischemic Heart Disease G.B. John Mancini, MD, Gilbert Gosselin,

Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology/Canadian Society of Cardiac Surgery Position Statement on Revascularization—Multivessel.

2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease Glenn N. Levine, MD, FACC, FAHA,

Carotid Sinus Massage in Patients with Suspected Acute Myocardial Infarction, Tachycardia, and Left Bundle Branch Block Teddy Weiss, MD, Yair Elitzur,

Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy Jean-François Tanguay, MD, CSPQ, FRCPC, FACC,

Laszlo Littmann, MD, PhD The American Journal of Medicine

Kay Lee Park, MD, Robert J. Goldberg, PhD, Frederick A

Attributable Cost and Length of Stay for Patients with Enoxaparin-Associated Bleeding Surasak Saokaew, PharmD, Narinee Khaisombat, MSc, Nathorn Chaiyakunapruk,

Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris Toshihiro Fukui,

Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.

R. Scott Wright, MD, Stephen L. Kopecky, MD, Guy S. Reeder, MD

Measure-specific reasons for exclusion (2010-Q4–2013-Q3).

Nat. Rev. Cardiol. doi: /nrcardio

2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Jason G. Andrade, MD, Atul Verma, MD,

Recent Temporal Changes in Atherosclerotic Cardiovascular Diseases in Ontario: Clinical and Health Systems Impact Jack V. Tu, MD, PhD, Anam M. Khan,

General anaesthesia in a patient with Brugada syndrome

2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy

Symptoms of Disturbed Sleep Predict Major Adverse Cardiac Events After Percutaneous Coronary Intervention Nisha M. Fernandes, MD, Lynne E. Nield, MD,

Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter

Acute coronary syndromes: diagnosis

Successful Use of Ranolazine in a Patient With Vasospastic Angina

Canadian Cardiovascular Society/Canadian Cardiovascular Critical Care Society/Canadian Association of Interventional Cardiology Position Statement on.

From Primary to Secondary Percutaneous Coronary Intervention: The Emerging Concept of Early Mechanical Reperfusion With Delayed Facilitated Stenting—When.

Any, acute and subacute stent thrombosis with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction.

Major bleeding with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction (STEMI) studies; (A) glycoprotein.

Baseline Q Waves and Time From Symptom Onset to ST-segment Elevation Myocardial Infarction: Insights From PLATO on the Influence of Sex Naji Kholaif,

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

Ticagrelor versus prasugrel; risk ratio with 95% CIs for the primary composite end point, primary composite end point in those undergoing PCI, myocardial.

Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 1: Non-ST–Segment.

Major bleeding with bivalirudin versus unfractionated heparin (UFH) in predominantly non-ST segment elevation acute coronary syndrome (NSTE-ACS) studies;

2019 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Guidelines on the Acute Management of ST-Elevation Myocardial Infarction:

The Clinical Significance and Management Implications of Chronic Total Occlusion Associated With Surgical Coronary Artery Revascularization Lorenzo Azzalini,

Mobile Medicine: Digital Dynamo or Virtual Vaporware

Targeted Therapeutic Drug Monitoring for Direct Oral Anticoagulants: What Is Its Potential Place and Can It Limit Black Swan Events? D. George Wyse,

R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R

Presentation transcript:

Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 2: ST-Segment Elevation Myocardial Infarction David H. Fitchett, MD, Pierre Theroux, MD, James M. Brophy, MD, PhD, Warren J. Cantor, MD, Jafna L. Cox, MD, Milan Gupta, MD, Heather Kertland, PharmD, Shamir R. Mehta, MD, MSc, Robert C. Welsh, MD, Shaun G. Goodman, MD, MSc Canadian Journal of Cardiology Volume 27, Issue 6, Pages S402-S412 (November 2011) DOI: 10.1016/j.cjca.2011.08.107 Copyright © 2011 Canadian Cardiovascular Society Terms and Conditions

Figure 1 STEMI algorithm. * This time may be extended to 120 minutes for late presenters (symptoms ≥ 3 hours) or high TIMI STEMI risk score. ** Consider fibrinolytic therapy prior to transfer if transfer distance very far and patient at low risk for bleeding complications. ASA, aspirin; ECG, electrocardiogram; ICH, intracranial hemorrhage; IV, intravenous; MI, myocardial infarction; PCI, percutaneous coronary intervention; p.o., orally; STEMI, ST-segment elevation MI; TIMI, Thrombolysis in MI. UFH, unfractionated heparin. Canadian Journal of Cardiology 2011 27, S402-S412DOI: (10.1016/j.cjca.2011.08.107) Copyright © 2011 Canadian Cardiovascular Society Terms and Conditions

Figure 2 TIMI STEMI risk score. h/o, history of; HTN, hypertension; LBBB, left bundle branch block; STE, ST elevation; STEMI, ST-segment elevation myocardial infarction; TIMI, Thrombolysis in Myocardial Infarction. Reprinted with permission from Morrow et al.38 Canadian Journal of Cardiology 2011 27, S402-S412DOI: (10.1016/j.cjca.2011.08.107) Copyright © 2011 Canadian Cardiovascular Society Terms and Conditions